This brand name is authorized in Nigeria.
The drug CLINIVAL-V contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
EH6D7113I8 - CLINDAMYCIN PHOSPHATE
|
|
Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes and a wide range of anaerobic bacteria. Lincosamides such as clindamycin bind to the 50S subunit of the bacterial ribosome and inhibit the early stages of protein synthesis. |
|
2
|
UNII
G07GZ97H65 - CLOTRIMAZOLE
|
|
Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the fungal cytoplasmic membrane. Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| A4-6106 | Suppository | Clinival-V Suppositories SUPP 100 mg; 100 mg 10 x 1 x 7's | Each vaginal suppository contains: Clindamycin Phosphate equiv. to Clindamycin 100 mg, Clotrimazole 100 mg | 20/12/2019 |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | A4-6106 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.